Amanitins及其作为抗体-药物偶联物有效载荷的发展

Q1 Pharmacology, Toxicology and Pharmaceutics

Drug Discovery Today: Technologies Pub Date : 2018-12-01 DOI:10.1016/j.ddtec.2018.08.005

Andreas Pahl, Christian Lutz, Torsten Hechler

{"title":"Amanitins及其作为抗体-药物偶联物有效载荷的发展","authors":"Andreas Pahl, Christian Lutz, Torsten Hechler","doi":"10.1016/j.ddtec.2018.08.005","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>Amanitin-based ADCs represent a new class of ADCs using a novel mode of action. This payload introduces a novel mode of action into oncology therapy, the inhibition of RNA Polymerase II. The high potency of the toxin leads to highly efficacious ADCs. The development of the technology around this toxin will be described. These developments support the clinical development of amanitin-based ADCs by using a toxin with a new mode of action and with a favorable therapeutic index. HDP-101 is an </span>Amanitin based ADC directed against </span>BCMA and will be advancing to the clinical phase in 2019.</p></div>","PeriodicalId":36012,"journal":{"name":"Drug Discovery Today: Technologies","volume":"30 ","pages":"Pages 85-89"},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddtec.2018.08.005","citationCount":"60","resultStr":"{\"title\":\"Amanitins and their development as a payload for antibody-drug conjugates\",\"authors\":\"Andreas Pahl, Christian Lutz, Torsten Hechler\",\"doi\":\"10.1016/j.ddtec.2018.08.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span>Amanitin-based ADCs represent a new class of ADCs using a novel mode of action. This payload introduces a novel mode of action into oncology therapy, the inhibition of RNA Polymerase II. The high potency of the toxin leads to highly efficacious ADCs. The development of the technology around this toxin will be described. These developments support the clinical development of amanitin-based ADCs by using a toxin with a new mode of action and with a favorable therapeutic index. HDP-101 is an </span>Amanitin based ADC directed against </span>BCMA and will be advancing to the clinical phase in 2019.</p></div>\",\"PeriodicalId\":36012,\"journal\":{\"name\":\"Drug Discovery Today: Technologies\",\"volume\":\"30 \",\"pages\":\"Pages 85-89\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ddtec.2018.08.005\",\"citationCount\":\"60\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Discovery Today: Technologies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1740674918300350\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today: Technologies","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1740674918300350","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 60

摘要

基于amanita的adc代表了一类新的adc，使用一种新的作用模式。这种有效载荷为肿瘤治疗引入了一种新的作用模式，即抑制RNA聚合酶II。毒素的高效力导致了高效的adc。本文将描述围绕这种毒素的技术的发展。这些进展通过使用一种具有新作用模式和良好治疗指数的毒素，支持了基于amanita的adc的临床开发。HDP-101是一种基于Amanitin的针对BCMA的ADC，将于2019年进入临床阶段。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Amanitins and their development as a payload for antibody-drug conjugates

查看原文本刊更多论文

Amanitins and their development as a payload for antibody-drug conjugates

Amanitin-based ADCs represent a new class of ADCs using a novel mode of action. This payload introduces a novel mode of action into oncology therapy, the inhibition of RNA Polymerase II. The high potency of the toxin leads to highly efficacious ADCs. The development of the technology around this toxin will be described. These developments support the clinical development of amanitin-based ADCs by using a toxin with a new mode of action and with a favorable therapeutic index. HDP-101 is an Amanitin based ADC directed against BCMA and will be advancing to the clinical phase in 2019.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drug Discovery Today: Technologies Pharmacology, Toxicology and Pharmaceutics-Drug Discovery

自引率

0.00%

发文量

期刊介绍： Discovery Today: Technologies compares different technological tools and techniques used from the discovery of new drug targets through to the launch of new medicines.